文献速递神经肌肉病

肌萎缩侧索硬化相关致病变异共存与预后的关联

Association of Copresence of Pathogenic Variants Related to Amyotrophic Lateral Sclerosis and Prognosis.
PubMed 文献 · Neurology · 2023-05-18

研究基于2007至2016年皮埃蒙特肌萎缩侧索硬化登记处的1245例患者及766名对照,分析UNC13A、CAMTA1、SLC11A2、ZNF512B变异及ATXN2、C9orf72重复扩增对生存的独立与交互影响。结果显示C9orf72、ATXN2、UNC13A C/C显著缩短生存,CAMTA1在Cox多变量分析中亦与生存独立相关(HR 1.13,95%CI 1.001-1.30,P=0.048),且两个有害等位基因/扩增共存与更短生存相关。

要点

  • C9orf72、ATXN2≥31和UNC13A C/C在单变量分析中显著缩短生存。
  • CAMTA1在Cox多变量分析中与生存独立相关(HR 1.13,95%CI 1.001-1.30,P=0.048)。
  • 两个有害等位基因/扩增共存与更短生存相关,且各对应对特定临床表型。

核心结论

  • 与肌萎缩侧索硬化生存或表型相关的修饰基因变异可单独或共同发挥作用。
  • 54%的患者携带至少1个有害常见变异或重复扩增,强调研究发现的临床影响。
  • 修饰基因交互效应的识别是解释肌萎缩侧索硬化临床异质性的关键线索,在设计与解读临床试验结果时应予以考虑。

研究设计与样本

  • 研究人群为2007至2016年通过皮埃蒙特肌萎缩侧索硬化登记处识别的1245例肌萎缩侧索硬化患者,且不携带超氧化物歧化酶1型、TAR DNA结合蛋白和肉瘤融合蛋白致病性变异。
  • 对照为766名与病例年龄、性别和地理匹配的意大利参与者。
  • 检测UNC13A(rs12608932)、CAMTA1(rs2412208)、SLC11A2(rs407135)、ZNF512B(rs2275294)变异,以及ATXN2 polyQ中间重复(≥31)和C9orf72 GGGGCC内含子扩增(≥30)。

主要发现

  • 整个队列的中位生存时间为2.67年(四分位距[IQR] 1.67-5.25)。
  • 单变量分析中,仅C9orf72(2.51年,IQR 1.74-3.82;p=0.016)、ATXN2(1.82年,IQR 1.08-2.33;p<0.001)和UNC13A C/C(2.3年,IQR 1.3-3.9;p<0.001)显著降低生存。
  • Cox多变量分析中,CAMTA1也显示与生存独立相关(风险比1.13,95%CI 1.001-1.30,p=0.048)。
  • 两个有害等位基因/扩增共存与更短生存相关:CAMTA1 G/G+G/T与UNC13A C/C共存患者中位生存1.67年(1.16-3.08),不携带这些变异者为2.75年(1.67-5.26)(p<0.001);CAMTA1 G/G+G/T与ATXN2≥31中间polyQ重复共存者为1.75年(0.84-2.18)(p<0.001);ATXN2≥31 polyQ重复与UNC13A C/C共存者为1.33年(0.84-1.75)(p<0.001);C9ORF72≥30与UNC13A C/C共存者为1.66年(1.41-2.16)。
  • 每对有害等位基因/扩增与特定临床表型相关。

关键数值与推荐

  • ATXN2 polyQ中间重复定义为≥31。
  • C9orf72 GGGGCC内含子扩增定义为≥30。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Despite recent advances, it is not clear whether the various genes/genetic variants related to amyotrophic lateral sclerosis (ALS) interact in modifying patients' phenotype. The aim of this study was to determine whether the copresence of genetic variants related to ALS has interactive effects on the course of the disease. METHODS: The study population includes 1,245 patients with ALS identified through the Piemonte Register for ALS between 2007 and 2016 and not carrying superoxide dismutase type 1, TAR DNA binding protein, and fused in sarcoma pathogenic variants. Controls were 766 Italian participants age-matched, sex-matched, and geographically matched to cases. We considered Unc-13 homolog A (UNC13A) (rs12608932), calmodulin binding transcription activator 1 (CAMTA1) (rs2412208), solute carrier family 11 member 2 (SLC11A2) (rs407135), and zinc finger protein 512B (ZNF512B) (rs2275294) variants, as well as ataxin-2 (ATXN2) polyQ intermediate repeats (≥31) and chromosome 9 open reading frame 72 (C9orf72) GGGGCC intronic expansions (≥30). RESULTS: The median survival time of the whole cohort was 2.67 years (interquartile range [IQR] 1.67-5.25). In univariate analysis, only C9orf72 (2.51 years, IQR 1.74-3.82; p = 0.016), ATXN2 (1.82 years, IQR 1.08-2.33; p < 0.001), and UNC13A C/C (2.3 years, IQR 1.3-3.9; p < 0.001) significantly reduced survival. In Cox multivariable analysis, CAMTA1 also emerged to be independently related to survival (hazard ratio 1.13, 95% CI 1.001-1.30, p = 0.048). The copresence of 2 detrimental alleles/expansions was correlated with shorter survival. In particular, the median survival of patients with CAMTA1 G/G+G/T and UNC13A C/C alleles was 1.67 years (1.16-3.08) compared with 2.75 years (1.67-5.26) of the patients not carrying these variants (p < 0.001); the survival of patients with CAMTA1 G/G+G/T alleles and ATXN2 ≥31 intermediate polyQ repeats was 1.75 years (0.84-2.18) (p < 0.001); the survival of patients with ATXN2 ≥31 polyQ repeats and UNC13A C/C allele was 1.33 years (0.84-1.75) (p < 0.001); the survival of patients with C9ORF72 ≥30 and UNC13A C/C allele was 1.66 years (1.41-2.16). Each pair of detrimental alleles/expansions was associated to specific clinical phenotypes. DISCUSSION: We showed that gene variants acting as modifiers of ALS survival or phenotype can act on their own or in unison. Overall, 54% of patients carried at least 1 detrimental common variant or repeat expansion, emphasizing the clinical impact of our findings. In addition, the identification of the interactive effects of modifier genes represents a crucial clue for explaining ALS clinical heterogeneity and should be considered when designing and interpreting clinical trials results.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Chiò A, Moglia C, Canosa A, et al. Association of Copresence of Pathogenic Variants Related to Amyotrophic Lateral Sclerosis and Prognosis. Neurology. 2023. PMID: 37202167. doi:10.1212/WNL.0000000000207367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。